Dr Reddy’s has further advanced its clinical trial program for its DRL_TC proposed rival to Actemra/RoActemra (tocilizumab), after the intravenous version of the biosimilar candidate successfully completed a Phase I study.
The latest development comes after the subcutaneous version passed a Phase I trial late last year (see sidebar).






